> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rhythm Will Pay LG Chem $350 Million To Shrink Royalty On Its Obesity Drug Bivamelagon
- URL: https://www.bullished.co/rhythm-will-pay-lg-chem-350-million-to-shrink-royalty-on-its-obesity-drug-bivamelagon-dffcebcb/
- Published: 2026-11-03T14:29:30.000Z
- Updated: 2026-11-03T14:29:30.000Z
- Description: Rhythm will pay $350 million over four years and borrow up to $750 million to cut the royalty it owes on bivamelagon.
- Author: Matteo Parrino
- Tags: Earnings, RYTM, Industry: Healthcare

[Rhythm Pharmaceuticals](https://www.bullished.co/tag/rytm/), which develops and sells drugs for rare diseases of hunger and weight regulation, will pay LG Chem [$350 million](https://www.koreatimes.co.kr/business/companies/20261103/lg-chem-revises-licensing-deal-with-us-firm-for-obesity-drug?ref=bullished.co) in installments to buy down the royalty on bivamelagon, its next-generation obesity drug, executives said on the company's third-quarter earnings call Tuesday. Chief Executive Officer David Meeker said the old structure gave Rhythm an "economic disincentive to fully develop" the drug.

## The royalty buy-down

Chief Financial Officer Hunter Smith said on the call that Rhythm projected cross-portfolio royalty obligations of 5% to 7% under the previous agreement, pending future approvals for bivamelagon. The company is cutting that to 1% flat, assuming U.S. approval of the drug.

The [$350 million](https://www.koreatimes.co.kr/business/companies/20261103/lg-chem-revises-licensing-deal-with-us-firm-for-obesity-drug?ref=bullished.co) is paid in four installments: $70 million due 15 days from closing, then $100 million in September 2027, $100 million in September 2028 and $80 million in September 2029\. Smith said the present value of the total will be booked in the fourth quarter as research and development expense.

The $205 million in development and commercial milestones owed to LG Chem under the original deal is now payable on sales of the whole MC4R portfolio. LG Chem also gets an added $200 million milestone if sales reach $3 billion in a calendar year, a payment Smith said Rhythm would be "happy to make."

Smith said Rhythm tested the deal against risk-adjusted sell-side consensus and sees a "pretty good payback relatively quickly." Asked whether a rival royalty buyer was involved, he said Rhythm initiated the deal.

## Why Prader-Willi is in play

Meeker said broader use of bivamelagon would have driven a disproportionate royalty burden compared with developing RM-718, Rhythm's other next-generation drug. The original agreement also added an incremental royalty for new indications, which would have weighed on Prader-Willi syndrome, he said.

With the deal, Rhythm will engage regulators with the goal of starting a six-month phase three Prader-Willi trial in 2027, measuring hyperphagia (excessive hunger). A 52-week late-stage trial in hypothalamic obesity should dose its first patients in January. Meeker said Rhythm will lay out its wider MC4R portfolio strategy, including proprietary combinations, in 2027.

## Loan and launch numbers

To fund the deal, Rhythm [arranged a five-year term loan](https://www.globenewswire.com/news-release/2026/11/03/3393875/0/en/rhythm-pharmaceuticals-and-lg-chem-enter-into-amendment-to-bivamelagon-exclusive-license-agreement.html?ref=bullished.co) of up to $750 million. It will draw $250 million at first, at SOFR plus 4.6%, Smith said.

Rhythm ended the quarter with about $321 million in cash and investments, before loan proceeds. Global Imcivree sales were [$92.1 million](https://seekingalpha.com/news/4663302-rhythm-pharmaceuticals-gaap-eps-of-0%5F61-beats-by-0%5F10-revenue-of-92%5F1m-beats-by-7%5F5m?ref=bullished.co), up 29% from the second quarter, and $67.5 million of that came from the U.S. Net loss was $0.61 a share. The company's market value was $6.4 billion in Tuesday morning trading.

Rhythm said it launched Imcivree for acquired hypothalamic obesity in Japan on October 14, and Meeker expects Japan to become its second-largest market.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Rhythm Pharmaceuticals GAAP EPS of -$0.61 beats by $0.10, revenue of $92.1M beats by $7.5M (RYTM:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4663302-rhythm-pharmaceuticals-gaap-eps-of-0%5F61-beats-by-0%5F10-revenue-of-92%5F1m-beats-by-7%5F5m?ref=bullished.co) — seekingalpha.com
- [Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates](https://finance.yahoo.com/healthcare/articles/rhythm-pharmaceuticals-inc-rytm-reports-121504098.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [LG Chem revises licensing deal with US firm for obesity drug - The Korea Times](https://www.koreatimes.co.kr/business/companies/20261103/lg-chem-revises-licensing-deal-with-us-firm-for-obesity-drug?ref=bullished.co) — koreatimes.co.kr
- [Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial](https://rss.globenewswire.com/news-release/2026/11/03/3394041/0/en/rhythm-pharmaceuticals-reports-third-quarter-2026-financial-results-and-business-update.html?ref=bullished.co) — rss.globenewswire.com
- [Rhythm Pharmaceuticals and LG Chem Enter into Amendment to](https://www.globenewswire.com/news-release/2026/11/03/3393875/0/en/rhythm-pharmaceuticals-and-lg-chem-enter-into-amendment-to-bivamelagon-exclusive-license-agreement.html?ref=bullished.co) — globenewswire.com

### More on Rhythm Pharmaceuticals

- [JPMorgan Reports 5.1% Passive Stake In Rhythm Pharmaceuticals, 3,563,667 Shares](https://www.bullished.co/jpmorgan-reports-5-1-passive-stake-in-rhythm-pharmaceuticals-3-563-667-shares-aeb06e0c/)

[All Rhythm Pharmaceuticals (RYTM) coverage →](https://www.bullished.co/tag/rytm/)